Cohance Lifesciences Reports Mixed Financial Results Amid Sales Growth in March 2025

May 28 2025 08:53 PM IST
share
Share Via
Cohance Lifesciences has announced its financial results for the quarter ending March 2025, showcasing a mixed performance. While net sales reached Rs 402.02 crore, the company experienced declines in profitability metrics, with both Profit Before Tax and Profit After Tax falling compared to previous quarters.
Cohance Lifesciences has recently reported its financial results for the quarter ending March 2025, revealing a complex picture of performance within the pharmaceuticals and biotechnology sector. The company has experienced notable changes in its evaluation, with a score adjustment reflecting the current financial landscape.

On a positive note, Cohance Lifesciences achieved net sales of Rs 402.02 crore, marking a significant growth compared to the average of Rs 262.12 crore over the previous four quarters. This figure represents the highest net sales recorded in the last five quarters, indicating a favorable near-term sales trend.

Conversely, the company faced challenges in profitability metrics. Profit Before Tax (PBT) fell to Rs 41.03 crore, a decline from the average of Rs 74.53 crore in prior quarters, while Profit After Tax (PAT) decreased to Rs 42.01 crore, down from an average of Rs 69.81 crore. Additionally, the interest expense reached its highest level in five quarters at Rs 5.75 crore, suggesting increased borrowings and a decline in the company's ability to manage interest payments effectively.

Overall, the financial results for Cohance Lifesciences reflect a mixed performance, with significant evaluation changes noted in the latest assessment.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News